

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use BRAVNETSA safely and effectively. See full prescribing information for BRAVNETSA.

BRAVNETSA™ (lutetium Lu 177 dotatate) injection, for intravenous use
Initial U.S. Approval: 2018

RECENT MAJOR CHANGES	
Indications and Usage (1)	4/2024
Dosage and Administration (2.2, 2.5, 2.6)	4/2024
Warnings and Precautions (5.1)	4/2024

INDICATIONS AND USAGE
BRAVNETSA is a radiolabeled somatostatin analog indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. (1)

- DOSAGE AND ADMINISTRATION**
- Verify Pregnancy status of females of reproductive potential prior to initiating BRAVNETSA. (2.1)
 - Administer 7.4 GBq (200 mCi) every 8 weeks (± 1 week) for a total of 4 doses. (2.2)
 - Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each BRAVNETSA dose and short-acting octreotide for symptomatic management. (2.3)
 - Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing BRAVNETSA until disease progression or for 18 months following treatment initiation. (2.3)
 - Administer antiemetics before recommended amino acid solution. (2.3)
 - Initiate recommended intravenous amino acid solution 30 minutes before BRAVNETSA infusion; continue during and for at least 3 hours after BRAVNETSA infusion. Do not decrease dose of amino acid solution if BRAVNETSA dose is reduced. (2.3)

DOSAGE FORMS AND STRENGTHS
Injection: 370 MBq/mL (10 mCi/mL) in single-dose vial. (3)

CONTRAINDICATIONS
None. (4)

WARNINGS AND PRECAUTIONS

- **Risk from Radiation Exposure:** Minimize radiation exposure during and after treatment with BRAVNETSA consistent with institutional good radiation safety practices and patient management procedures. (2.1, 5.1)
- **Myelosuppression:** Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue based on the severity. (2.4, 5.2)
- **Secondary Myelodysplastic Syndrome (MDS) and Leukemia:** Median time to onset: MDS is 29 months; acute leukemia is 55 months. (5.3)
- **Renal Toxicity:** Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of BRAVNETSA. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue based on the severity. (2.3, 2.4, 5.4)
- **Hepatotoxicity:** Monitor transaminases, bilirubin, serum albumin, and INR. (2.4, 5.5)
- **Hypersensitivity Reactions:** Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis. Permanently discontinue BRAVNETSA based on severity. (2.3, 2.4, 5.6)
- **Neuroendocrine Hormonal Crisis:** Monitor for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms. (5.7)
- **Embryo-Fetal Toxicity:** Can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.8, 8.1, 8.3)
- **Risk of Infertility:** BRAVNETSA may cause infertility. (5.9, 8.3)

ADVERSE REACTIONS
Most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence in BRAVNETSA arm) are lymphopenia, increased GGT, vomiting, nausea, increased AST, increased ALT, hyperglycemia and hypokalemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Lantheus Medical Imaging, Inc. at 1-800-362-2668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
Somatostatin Analogs: Discontinue long-acting analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each BRAVNETSA dose. (2.3, 7.1)

USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1	INDICATIONS AND USAGE
2	DOSAGE AND ADMINISTRATION
2.1	Important Safety Instructions
2.2	Recommended Dosage
2.3	Premedications and Concomitant Medications
2.4	Dosage Modifications for Adverse Reactions
2.5	Preparation and Administration
2.6	Radiation Dosimetry
3	DOSAGE FORMS AND STRENGTHS
4	CONTRAINDICATIONS
5	WARNINGS AND PRECAUTIONS
5.1	Risk From Radiation Exposure
5.2	Myelosuppression
5.3	Secondary Myelodysplastic Syndrome and Leukemia
5.4	Renal Toxicity
5.5	Hepatotoxicity
5.6	Hypersensitivity Reactions
5.7	Neuroendocrine Hormonal Crisis
5.8	Embryo-Fetal Toxicity
5.9	Risk of Infertility
6	ADVERSE REACTIONS
6.1	Clinical Trials Experience
6.2	Postmarketing Experience
7	DRUG INTERACTIONS
7.1	Somatostatin Analogs
7.2	Glucocorticoids
8	USE IN SPECIFIC POPULATIONS
8.1	Pregnancy

8.2	Lactation
8.3	Females and Males of Reproductive Potential
8.4	Pediatric Use
8.5	Geriatric Use
8.6	Renal Impairment
8.7	Hepatic Impairment
11	DESCRIPTION
11.1	Physical Characteristics
11.2	External Radiation
12	CLINICAL PHARMACOLOGY
12.1	Mechanism of Action
12.2	Pharmacodynamics
12.3	Pharmacokinetics
13	NONCLINICAL TOXICOLOGY
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2	Animal Toxicology and/or Pharmacology
14	CLINICAL STUDIES
14.1	Progressive, Well-Differentiated Advanced or Metastatic Somatostatin Receptor-Positive Midgut Carcinoid Tumors
14.2	Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors
16	HOW SUPPLIED/STORAGE AND HANDLING
17	PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing information are not listed.	

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BRAVNETSA is indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

2 DOSAGE AND ADMINISTRATION

2.1 Important Safety Instructions

BRAVNETSA is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see [Warnings and Precautions \(5.1\)](#)]. Use waterproof gloves and effective radiation shielding when handling BRAVNETSA. Radiopharmaceuticals, including BRAVNETSA, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

Verify pregnancy status of females of reproductive potential prior to initiating BRAVNETSA [see [Use in Specific Populations \(8.1, 8.3\)](#)].

Monitor patients closely for signs and symptoms of hypersensitivity reactions during and following the BRAVNETSA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available [see [Warnings and Precautions \(5.6\)](#)].

2.2 Recommended Dosage

The recommended BRAVNETSA dosage for adult patients is 7.4 GBq (200 mCi) every 8 weeks ($\pm$ 1 week) for a total of 4 doses. Administer premedications and concomitant medications as recommended [see [Dosage and Administration \(2.3\)](#)].

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator

Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

2.3 Premedications and Concomitant Medications

Somatostatin Analogs

- Before initiating BRAVNETSA treatment: Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) at least 4 weeks prior to initiating BRAVNETSA. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating BRAVNETSA [see [Drug Interactions \(7.1\)](#)].
- During BRAVNETSA treatment: Administer long-acting octreotide 30 mg intramuscularly between 4 to 24 hours after each BRAVNETSA dose. Do not administer long-acting octreotide within 4 weeks prior to each subsequent BRAVNETSA dose. Short-acting octreotide may be given for symptomatic management during BRAVNETSA treatment, but must be withheld at least 24 hours before each BRAVNETSA dose.
- Following BRAVNETSA treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing BRAVNETSA until disease progression or for 18 months following treatment initiation at the discretion of the physician.

Antiemetics

Administer antiemetics before the recommended amino acid solution.

Amino Acid Solution

Initiate an intravenous infusion of a sterile amino acid solution containing L-lysine and L-arginine ([Table 1](#)) 30 minutes before the start of the BRAVNETSA infusion. Use a three-way valve to administer the amino acid solution using the same venous access as BRAVNETSA or administer the amino acid solution through a separate venous access in the patient's other arm. Continue the amino acid solution infusion during and for at least 3 hours after completion of the BRAVNETSA infusion. Do not decrease the dose of the amino acid solution if a reduced dose of BRAVNETSA is administered [see [Warnings and Precautions \(5.4\)](#)].

Table 1. Amino Acid Solution

Item	Specification
L-lysine HCl	Between 18 g and 25 g ^a
L-arginine HCl	Between 18 g and 25 g ^b
Volume	1 to 2 L
Osmolality	< 1200 mOsmol/kg

^aequivalent to 14.4 to 20 g L-lysine

^bequivalent to 14.9 to 20.7 g L-arginine.

Hypersensitivity Prophylaxis

Premedicate patients who have had prior Grade 1 or 2 hypersensitivity reactions to BRAVNETSA. Do not re-challenge patients who experience Grade 3 or 4 hypersensitivity reactions to BRAVNETSA [see *Warnings and Precautions* (5.6)].

2.4 Dosage Modifications for Adverse Reactions

Recommended dose modifications of BRAVNETSA for adverse reactions are provided in Table 2.

Table 2. Recommended Dosage Modifications of BRAVNETSA for Adverse Reactions

Adverse Reaction	Severity of adverse reaction ^a	Dose Modification
Thrombocytopenia [see <i>Warnings and Precautions</i> (5.2)]	First occurrence of Grade 2, 3, or 4	Withhold dose until complete or partial resolution (Grade 0 to 1). Resume BRAVNETSA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 2, 3, or 4 thrombocytopenia, administer BRAVNETSA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue BRAVNETSA for Grade 2 or higher thrombocytopenia requiring a dosing interval beyond 16 weeks.
	Recurrent Grade 2, 3, or 4	Permanently discontinue BRAVNETSA.
Anemia and Neutropenia [see <i>Warnings and Precautions</i> (5.2)]	First occurrence of Grade 3 or 4	Withhold dose until complete or partial resolution (Grade 0, 1, or 2). Resume BRAVNETSA at

		3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 anemia or neutropenia, administer BRAVNETSA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue BRAVNETSA for Grade 3 or higher anemia or neutropenia requiring a dosing interval beyond 16 weeks.
	Recurrent Grade 3 or 4	Permanently discontinue BRAVNETSA.
Renal Toxicity [<i>see Warnings and Precautions (5.4)</i>]	First occurrence of: • Creatinine clearance less than 40 mL/min; calculated using Cockcroft-Gault formula with actual body weight, or • 40% increase from baseline serum creatinine, or • 40% decrease from baseline creatinine clearance; calculated using Cockcroft-Gault formula with actual body weight	Withhold dose until resolution or return to baseline. Resume BRAVNETSA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced dose does not result in renal toxicity, administer BRAVNETSA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue BRAVNETSA for renal toxicity requiring a dosing interval beyond 16 weeks.
	Recurrent renal toxicity	Permanently discontinue BRAVNETSA.
Hepatotoxicity [<i>see Warnings and Precautions (5.5)</i>]	First occurrence of: • Bilirubinemia greater than 3 times the upper limit of normal (Grade 3 or 4), or	Withhold dose until resolution or return to baseline.

	Serum albumin less than 30 g/L with international normalized ratio (INR) > 1.5.	Resume BRAVNETSA at 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If reduced BRAVNETSA dose does not result in hepatotoxicity, administer BRAVNETSA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue BRAVNETSA for hepatotoxicity requiring a dosing interval beyond 16 weeks.
	Recurrent hepatotoxicity	Permanently discontinue BRAVNETSA.
Hypersensitivity Reactions ^b [see <i>Warnings and Precautions</i> (5.6)]	First occurrence of Grade 3 or 4	Permanently discontinue BRAVNETSA.
Any Other Adverse Reactions ^c [see <i>Adverse Reactions</i> (6.1)]	First occurrence of Grade 3 or 4	Withhold dose until complete or partial resolution (Grade 0 to 2). Resume BRAVNETSA at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If reduced dose does not result in Grade 3 or 4 toxicity, administer BRAVNETSA at 7.4 GBq (200 mCi) as next dose. Permanently discontinue BRAVNETSA for Grade 3 or higher adverse reactions requiring a dosing interval beyond 16 weeks.
	Recurrent Grade 3 or 4	Permanently discontinue BRAVNETSA.

^aGrading of severity is defined in the most current Common Terminology Criteria for Adverse Events (CTCAE).

^bIncluding allergic reaction and anaphylaxis.

^cNo dose modification required for hematological toxicities Grade 3 or Grade 4 solely due to lymphopenia.

2.5 Preparation and Administration

Preparation Instructions

- Use aseptic technique and radiation shielding when handling or administering the BRAVNETSA solution. Use tongs when handling the vial to minimize radiation exposure.
- Inspect the product visually under a shielded screen for particulate matter and discoloration prior to administration. Discard the vial if particulates and/or discoloration are present.
- Do not inject the BRAVNETSA solution directly into any other intravenous solution.
- Confirm the amount of radioactivity of BRAVNETSA delivered to the patient with an appropriate dose calibrator prior to and after each BRAVNETSA administration.
- Dispose of any unused medicinal product or waste material in accordance with local and federal laws.

Administration Instructions

- Prior to administration, flush the intravenous catheter used for BRAVNETSA administration with ≥ 10 mL of 0.9% Sodium Chloride Injection, USP to ensure patency and to minimize the risk of extravasation. Manage cases of extravasation as per institutional guidelines.
- The gravity method, peristaltic pump method, or the syringe pump method may be used for the administration of the recommended dosage. Do not administer BRAVNETSA as an intravenous bolus.
- When using the gravity or peristaltic pump method, infuse BRAVNETSA injection directly from its original container.
- Use the peristaltic pump or syringe pump method when administering a reduced dose of BRAVNETSA following a dosage modification for an adverse reaction. When using the gravity method for a reduced dose, adjust the BRAVNETSA dose before the administration to avoid the delivery of an incorrect volume of BRAVNETSA.

Intravenous Methods of Administration

Instructions for the Gravity Method

- Insert a 2.5 cm, 20-gauge needle (short needle) into the BRAVNETSA vial and connect via a catheter to 500 mL 0.9% Sodium Chloride Injection, USP (used to transport the BRAVNETSA solution during the infusion). Ensure that the short needle does not touch the BRAVNETSA solution in the vial and do not connect this short needle directly to the patient. Do not allow the 0.9% Sodium Chloride Injection, USP to flow into the BRAVNETSA vial prior to the initiation of the infusion of

BRAVNETSA and do not inject the BRAVNETSA solution directly into the 0.9% Sodium Chloride Injection, USP.

- Insert a second needle that is 9 cm, 18-gauge (long needle) into the BRAVNETSA vial ensuring that this long needle touches and is secured to the bottom of the BRAVNETSA vial during the entire infusion. Connect the long needle to the patient by an intravenous catheter that is pre-filled with 0.9% Sodium Chloride Injection, USP and that is used for the BRAVNETSA infusion into the patient.
- Use a clamp or an infusion pump to regulate the flow of the 0.9% Sodium Chloride Injection, USP via the short needle into the BRAVNETSA vial at a rate of 50 mL/hour to 100 mL/hour for 5 to 10 minutes and then 200 mL/hour to 300 mL/hour for an additional 25 to 30 minutes (the 0.9% Sodium Chloride Injection, USP entering the vial through the short needle will carry the BRAVNETSA solution from the vial to the patient via the intravenous catheter connected to the long needle over a total duration of 30 to 40 minutes).
- During the infusion, ensure that the level of solution in the BRAVNETSA vial remains constant.
- Disconnect the vial from the long needle line and clamp the 0.9% Sodium Chloride Injection, USP line once the level of radioactivity is stable for at least five minutes.
- Follow the infusion with an intravenous flush of 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient.

Instructions for the Peristaltic Pump Method

- Insert a filtered 2.5 cm, 20-gauge needle (short venting needle) into the BRAVNETSA vial. Ensure that the short needle does not touch the BRAVNETSA solution in the vial and do not connect this short needle directly to the patient or to the peristaltic pump.
- Insert a second needle that is 9 cm, 18-gauge (long needle) into the BRAVNETSA vial ensuring that the long needle touches and is secured to the bottom of the BRAVNETSA vial during the entire infusion. Connect the long needle and a 0.9% Sodium Chloride Injection, USP to a 3-way stopcock valve via appropriate tubing.
- Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic pump according to manufacturer's instructions.
- Prime the line by opening the 3-way stopcock valve and pumping the BRAVNETSA solution through the tubing until it reaches the exit of the valve.
- Prime the intravenous catheter that will be connected to the patient by opening the 3-way stopcock valve to the 0.9% Sodium Chloride Injection, USP and pumping the 0.9% Sodium Chloride Injection, USP until it exits the end of the catheter tubing.
- Connect the primed intravenous catheter to the patient and set the 3-way stopcock valve such that the BRAVNETSA solution is in line with the peristaltic pump.
- Infuse an appropriate volume of BRAVNETSA solution over a 30-40 min period to deliver the desired radioactivity.

- When the desired BRAVNETSA radioactivity has been delivered, stop the peristaltic pump and then change the position of the 3-way stopcock valve so that the peristaltic pump is in line with the 0.9% Sodium Chloride Injection, USP. Restart the peristaltic pump and infuse an intravenous flush of 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient.

Instructions for the Syringe Pump Method

- Withdraw an appropriate volume of BRAVNETSA solution to deliver the desired radioactivity by using a disposable syringe fitted with a syringe shield and a disposable sterile needle that is 9 cm, 18-gauge (long needle). To aid the withdrawal of the solution, a filtered 2.5 cm, 20-gauge needle (short venting needle) can be used to reduce the resistance from the pressurized vial. Ensure that the short needle does not touch the BRAVNETSA solution in the vial.
- Fit the syringe into the shielded pump and include a 3-way stopcock valve between the syringe and an intravenous catheter pre-filled with 0.9% Sodium Chloride Injection, USP and used for BRAVNETSA administration to the patient.
- Infuse an appropriate volume of BRAVNETSA solution over a 30-40 min period to deliver the desired radioactivity.
- When the desired BRAVNETSA radioactivity has been delivered, stop the syringe pump and then change the position of the 3-way stopcock valve to flush the syringe with 25 mL of 0.9% Sodium Chloride Injection, USP. Restart the syringe pump.
- After the flush of the syringe has been completed, perform an intravenous flush with 25 mL of 0.9% Sodium Chloride Injection, USP through the intravenous catheter to the patient.

2.6 Radiation Dosimetry

The maximum penetration of lutetium-177 in tissue is 2.2 mm and the mean penetration is 0.67 mm. The mean and standard deviation (SD) of the estimated radiation absorbed doses for adults receiving Lutetium Lu 177 dotatate injection are shown in [Table 3](#).

Table 3. Estimated Radiation Absorbed Dose for Lutetium Lu 177 dotatate injection in Adults in NETTER-1

Organ	Absorbed dose per unit activity (Gy/GBq) (N=20)		Calculated absorbed dose for 4 x 7.4 GBq (29.6 GBq cumulative activity) (Gy)	
	Mean	SD	Mean	SD
Adrenals	0.037	0.016	1.1	0.5
Brain	0.027	0.016	0.8	0.5
Breasts	0.027	0.015	0.8	0.4
Gallbladder wall	0.042	0.019	1.2	0.6
Heart wall	0.032	0.015	0.9	0.4
Kidneys	0.654	0.295	19.4	8.7
Liver ^a	0.299	0.226	8.9	6.7
Lower large intestine wall	0.029	0.016	0.9	0.5
Lungs	0.031	0.015	0.9	0.4
Muscle	0.029	0.015	0.8	0.4
Osteogenic cells	0.151	0.268	4.5	7.9
Ovaries ^b	0.031	0.013	0.9	0.4
Pancreas	0.038	0.016	1.1	0.5
Red marrow ^c	0.035	0.029	1.0	0.8
Skin	0.027	0.015	0.8	0.4
Small intestine	0.031	0.015	0.9	0.5
Spleen	0.846	0.804	25.1	23.8
Stomach wall	0.032	0.015	0.9	0.5
Testes ^d	0.026	0.018	0.8	0.5
Thymus	0.028	0.015	0.8	0.5
Thyroid	0.027	0.016	0.8	0.5
Total body	0.052	0.027	1.6	0.8
Upper large intestine wall	0.032	0.015	0.9	0.4
Urinary bladder wall	0.437	0.176	12.8	5.3
Uterus ^b	0.032	0.013	1.0	0.4

^aN = 18 (two patients excluded because the liver absorbed dose was biased by the uptake of the liver metastases).

^bN = 9 (female patients only).

^cRed marrow dosimetry estimates were determined using blood radioactivity.

^dN = 11 (male patients only).

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

3 DOSAGE FORMS AND STRENGTHS

Injection: 370 MBq/mL (10 mCi/mL) of lutetium Lu 177 dotatate as a clear and colorless to slightly yellow solution in a single-dose vial.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Risk From Radiation Exposure

BRAVNETSA contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of BRAVNETSA are greater in pediatric patients than in adults [see *Use in Specific Populations* (8.4)].

Radiation can be detected in the urine for up to 30 days following BRAVNETSA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with BRAVNETSA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home [see *Dosage and Administration* (2.1), *Clinical Pharmacology* (12.3)].

5.2 Myelosuppression

In NETTER-1, myelosuppression occurred more frequently in patients receiving Lutetium Lu 177 dotatate injection with long-acting octreotide compared to patients receiving high-dose long-acting octreotide (all grades/grade 3 or 4): anemia (81%/0) versus (54%/1%); thrombocytopenia (53%/1%) versus (17%/0); and neutropenia (26%/3%) versus (11%/0). In NETTER-1, platelet nadir occurred at a median of 5.1 months following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the nineteen patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to Grade 1, 9 to Grade 2, and 1 to Grade 3.

Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of myelosuppression [see [Dosage and Administration \(2.4\)](#)].

5.3 Secondary Myelodysplastic Syndrome and Leukemia

In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (MDS) was reported in 2.3% of patients receiving Lutetium Lu 177 dotatate injection with long-acting octreotide compared to no patients receiving high-dose long-acting octreotide.

In ERASMUS, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to onset was 29 months (9 to 45 months) for MDS and 55 months (32 to 125 months) for acute leukemia.

5.4 Renal Toxicity

In ERASMUS, 8 patients (<1%) developed renal failure 3 to 36 months following Lutetium Lu 177 dotatate injection. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis.

Administer the recommended amino acid solution before, during and after BRAVNETSA [see [Dosage and Administration \(2.3\)](#)] to decrease the reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of BRAVNETSA.

Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of renal toxicity [see [Dosage and Administration \(2.4\)](#)].

Patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure [see [Use in Specific Populations \(8.6\)](#)]

5.5 Hepatotoxicity

In ERASMUS, 2 patients (< 1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure.

Monitor transaminases, bilirubin, serum albumin, and international normalized ratio (INR) during treatment. Withhold dose, reduce dose, or permanently discontinue BRAVNETSA based on the severity of hepatotoxicity [see [Dosage and Administration \(2.4\)](#)].

5.6 Hypersensitivity Reactions

Hypersensitivity reactions, including angioedema, occurred in patients treated with Lutetium Lu 177 dotatate injection [see [Adverse Reactions \(6.2\)](#)]. Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following BRAVNETSA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available. Discontinue the infusion upon the first observation of any signs or symptoms consistent with a severe hypersensitivity reaction and initiate appropriate therapy.

Premedicate patients with a history of Grade 1 or 2 hypersensitivity reactions to BRAVNETSA before subsequent doses [see [Dosage and Administration \(2.3\)](#)]. Permanently discontinue BRAVNETSA in patients who experience Grade 3 or 4 hypersensitivity reactions [see [Dosage and Administration \(2.4\)](#)].

5.7 Neuroendocrine Hormonal Crisis

Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm and hypotension, occurred in < 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial Lutetium Lu 177 dotatate injection dose. Two (< 1%) patients were reported to have hypercalcemia.

Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.

5.8 Embryo-Fetal Toxicity

Based on its mechanism of action, BRAVNETSA can cause fetal harm when administered to a pregnant woman [see [Clinical Pharmacology \(12.1\)](#)]. There are no available data on lutetium Lu 177 dotatate use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from BRAVNETSA, can cause fetal harm.

Verify pregnancy status of females of reproductive potential prior to initiating BRAVNETSA [see [Dosage and Administration \(2.1\)](#)].

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 7 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 4 months after the last dose [see *Use in Specific Populations* (8.1, 8.3)].

5.9 Risk of Infertility

BRAVNETSA may cause infertility in males and females. The recommended cumulative dose of 29.6 GBq of BRAVNETSA results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see *Dosage and Administration* (2.6) and *Use in Specific Populations* (8.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling.

- Myelosuppression [see *Warnings and Precautions* (5.2)]
- Secondary Myelodysplastic Syndrome and Leukemia [see *Warnings and Precautions* (5.3)]
- Renal Toxicity [see *Warnings and Precautions* (5.4)]
- Hepatotoxicity [see *Warnings and Precautions* (5.5)]
- Hypersensitivity Reactions [see *Warnings and Precautions* (5.6)]
- Neuroendocrine Hormonal Crisis [see *Warnings and Precautions* (5.7)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in WARNINGS AND PRECAUTIONS reflect exposure to Lutetium Lu 177 dotatate in 111 patients with advanced, progressive midgut neuroendocrine tumors (NETTER-1). Safety data in WARNINGS AND PRECAUTIONS were also obtained in an additional 22 patients in a non-randomized pharmacokinetic sub-study of NETTER-1 and in a subset of patients (811 of 1214) with advanced somatostatin receptor-positive tumors enrolled in ERASMUS [see *Warnings and Precautions* (5)].

Adult Population

NETTER-1

The safety data of Lutetium Lu 177 dotatate with octreotide was evaluated in NETTER-1 [see [Clinical Studies \(14.1\)](#)]. Patients with progressive, somatostatin receptor-positive midgut carcinoid tumors received Lutetium Lu 177 dotatate 7.4 GBq (200 mCi) administered every 8 to 16 weeks concurrently with the recommended amino acid solution and with long-acting octreotide (30 mg administered by intramuscular injection within 24 hours of each Lutetium Lu 177 dotatate dose) (N = 111), or high-dose octreotide (defined as long-acting octreotide 60 mg by intramuscular injection every 4 weeks) (N = 112) [see [Clinical Studies \(14.1\)](#)]. Among patients receiving Lutetium Lu 177 dotatate injection with octreotide, 79% received a cumulative dose > 22.2 GBq (> 600 mCi) and 76% of patients received all four planned doses. Six percent (6%) of patients required a dose reduction and 13% of patients discontinued Lutetium Lu 177 dotatate. Five patients discontinued Lutetium Lu 177 dotatate for renal-related events and 4 discontinued for hematological toxicities.

[Table 5](#) and [Table 6](#) summarize the incidence of adverse reactions and laboratory abnormalities, respectively. The most common Grade 3-4 adverse reactions occurring with a greater frequency among patients receiving Lutetium Lu 177 dotatate injection with octreotide compared to patients receiving high-dose octreotide include: lymphopenia (44%), increased gamma-glutamyltransferase (GGT) (20%), vomiting (7%), nausea and increased aspartate aminotransferase (AST) (5% each), and increased alanine aminotransferase (ALT), hyperglycemia and hypokalemia (4% each).

Table 5. Adverse Reactions Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 dotatate injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of $\geq 5\%$ All Grades or $\geq 2\%$ Grades 3-4)^a

Adverse Reaction ^a	Lutetium Lu 177 dotatate with long-acting Octreotide (30 mg) (N=111)		Long-acting Octreotide (60 mg) (N=112)	
	All Grades %	Grades 3-4 %	All Grades %	Grades 3-4 %
Gastrointestinal disorders				
Nausea	65	5	12	2
Vomiting	53	7	10	0
Abdominal pain	26	3	19	3
Diarrhea	26	3	18	1
Constipation	10	0	5	0
General disorders				

Fatigue	38	1	26	2
Peripheral edema	16	0	9	1
Pyrexia	8	0	3	0
Metabolism and nutrition disorders				
Decreased appetite	21	0	11	3
Nervous system disorders				
Headache	17	0	5	0
Dizziness	17	0	8	0
Dysgeusia	8	0	2	0
Vascular disorders				
Flushing	14	1	9	0
Hypertension	12	2	7	2
Musculoskeletal and connective tissue disorders				
Back pain	13	2	10	0
Pain in extremity	11	0	5	0
Myalgia	5	0	0	0
Neck pain	5	0	0	0
Renal and urinary disorders				
Renal failure ^b	13	3	4	1
Radiation-related urinary tract adverse reactions ^c	8	0	3	0
Psychiatric disorders				
Anxiety	12	1	5	0
Skin and subcutaneous tissue disorders				
Alopecia	12	0	2	0
Respiratory, thoracic and mediastinal disorders				
Cough	11	1	6	0
Cardiac disorders				
Atrial fibrillation	5	1	0	0

^aNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays adverse reactions occurring at a higher incidence in Lutetium Lu 177 dotatate-treated patients [between arm difference of $\geq 5\%$ (all Grades) or $\geq 2\%$ (Grades 3-4)].

^bIncludes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotemia, renal disorder, renal failure, renal impairment.

^cIncludes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence.

Table 6. Laboratory Abnormalities Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 dotatate injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of $\geq 5\%$ All Grades or $\geq 2\%$ Grades 3-4)^{a,b}

Laboratory abnormality ^b	Lutetium Lu 177 dotatate with long-acting Octreotide (30 mg) (N=111)		Long-acting Octreotide (60 mg) (N=112)	
	All Grades %	Grades 3-4 %	All Grades %	Grades 3-4 %
Hematology				
Lymphopenia	90	44	39	5
Anemia	81	0	55	1
Leukopenia	55	2	20	0
Thrombocytopenia	53	1	17	0
Neutropenia	26	3	11	0
Renal/Metabolic				
Creatinine increased	85	1	73	0
Hyperglycemia	82	4	67	2
Hyperuricemia	34	6	30	6
Hypocalcemia	32	0	14	0
Hypokalemia	26	4	21	2
Hyperkalemia	19	0	11	0
Hypernatremia	17	0	7	0
Hypoglycemia	15	0	8	0
Hepatic				
GGT increased	66	20	67	16
Alkaline phosphatase increased	65	5	55	9
AST increased	50	5	35	0
ALT increased	43	4	34	0
Blood bilirubin increased	30	2	28	0

^aValues are worst grade observed after randomization.

^bNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays laboratory abnormalities occurring at a higher incidence in Lutetium Lu 177 dotatate-treated patients [between arm difference of $\geq 5\%$ (all Grades) or $\geq 2\%$ (Grades 3-4)].

ERASMUS

Safety data are available from 1214 patients in ERASMUS, an international, single-institution, single-arm, open-label trial of patients with somatostatin receptor-positive tumors (neuroendocrine and other primaries). Patients received Lutetium Lu 177 dotatate injection 7.4 GBq (200 mCi) administered every 6 to 13 weeks with or without octreotide. Retrospective medical record review was conducted on a subset of 811 patients to document serious adverse reactions. Eighty-one (81%) percent of patients in the subset received a cumulative dose ≥ 22.2 GBq (≥ 600 mCi). With a median follow-up time of more than 4 years, the following rates of serious adverse reactions were reported: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%).

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of Lutetium Lu 177 dotatate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- *Immune System Disorders:* hypersensitivity reactions, including angioedema

7 DRUG INTERACTIONS

7.1 Somatostatin Analogs

Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of Lutetium Lu 177 dotatate. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each BRAVNETSA dose. Administer short- and long-acting octreotide during BRAVNETSA treatment as recommended [see [Dosage and Administration \(2.3\)](#)].

7.2 Glucocorticoids

Glucocorticoids can induce down-regulation of subtype 2 somatostatin receptors (SSTR2). Avoid repeated administration of high doses of glucocorticoids during treatment with BRAVNETSA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on its mechanism of action, Lutetium Lu 177 dotatate injection can cause fetal harm when administered to a pregnant woman [see *Clinical Pharmacology* (12.1)]. There are no available data on Lutetium Lu 177 dotatate use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from BRAVNETSA, can cause fetal harm. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

Risk Summary

There are no data on the presence of lutetium Lu 177 dotatate in human milk, or its effects on the breastfed child or milk production. No lactation studies in animals were conducted. Because of the potential risk for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with BRAVNETSA and for 2.5 months after the last dose.

8.3 Females and Males of Reproductive Potential

Based on mechanism of action, Lutetium Lu 177 dotatate injection can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations* (8.1)].

Pregnancy Testing

Verify pregnancy status of females of reproductive potential prior to initiating BRAVNETSA [see *Use in Specific Populations* (8.1)].

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 7 months after the last dose.

Males

Advise males with female partners of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 4 months after the last dose [see [Clinical Pharmacology \(12.1\)](#) and [Nonclinical Toxicology \(13.1\)](#)].

Infertility

The recommended cumulative dose of 29.6 GBq of Lutetium Lu 177 dotatate results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see [Dosage and Administration \(2.6\)](#)].

8.4 Pediatric Use

The risks of radiation exposure associated with BRAVNETSA are greater in pediatric patients than in adult patients due to longer life expectancy. Continued follow-up is recommended for evaluation of long-term effects.

The pharmacokinetic profile and safety of BRAVNETSA in pediatric patients 12 years and older with baseline renal impairment have not been studied.

The safety and effectiveness of BRAVNETSA have not been established in pediatric patients younger than 12 years old with somatostatin receptor-positive GEP-NETs.

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

8.5 Geriatric Use

Of the 1325 patients treated with lutetium Lu 177 dotatate injection in clinical trials, 438 patients (33%) were 65 years and older.

The response rate and the number of patients with a serious adverse event were similar to those of younger subjects.

No overall differences in safety or effectiveness were observed between older and younger patients.

8.6 Renal Impairment

No dose adjustment is recommended for patients with baseline mild to moderate (creatinine clearance 30 to 89 mL/min by Cockcroft-Gault formula) renal impairment. However, patients with baseline mild or moderate renal impairment may be at greater risk of toxicity, including renal toxicity, due to increased radiation exposure. Perform more frequent assessments of renal function in patients with baseline mild to moderate impairment. The pharmacokinetic profile and safety of Lutetium Lu 177 dotatate in patients with baseline severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault formula) or end-stage renal disease have not been studied [see *Warnings and Precautions* (5.4)].


8.7 Hepatic Impairment

No dose adjustment is recommended for patients with baseline mild or moderate hepatic impairment. The pharmacokinetic profile and safety of Lutetium Lu 177 dotatate in patients with baseline severe hepatic impairment (total bilirubin > 3 times upper limit of normal, regardless of AST level) have not been studied.

11 DESCRIPTION

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog. The drug substance lutetium Lu 177 dotatate is a cyclic peptide linked with the covalently bound chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid binding a non-carrier added lutetium 177 radionuclide.

Lutetium Lu 177 dotatate is described as lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10tetraazacyclododec-1-yl) acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic (2-7) disulfide. The molecular weight is 1609.6 Daltons and the structural formula is as follows:



BRAVNETSA (lutetium Lu 177 dotatate) 370 MBq/mL (10 mCi/mL) Injection is a sterile, clear, colorless to slightly yellow solution for intravenous use. Each single-dose vial contains acetic acid (0.48 mg/mL), sodium acetate (0.66 mg/mL), sodium hydroxide (0.65 mg/mL), ascorbic acid (2.8 mg/mL), diethylene triamine pentaacetic acid (0.05 mg/mL), sodium chloride (6.85 mg/mL), and Water for Injection (ad 1 mL). The pH range of the solution is 4.5 to 6.

11.1 Physical Characteristics

Lutetium-177 decays to stable hafnium-177 with a half-life of 6.647 days, by emitting beta-minus radiation with a maximum energy of 0.498 MeV (79%) and photonic radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.2%). The main radiations of lutetium-177 are detailed in [Table 7](#).

Table 7. Lutetium-177 Main Radiations

Radiation	Energy (keV)	I β -%	I γ %
β^-	176.5	12.2	
β^-	248.1	0.05	
β^-	384.9	9.1	
β^-	497.8	78.6	
γ	71.6		0.15
γ	112.9		6.20
γ	136.7		0.05
γ	208.4		11.0
γ	249.7		0.21
γ	321.3		0.22

11.2 External Radiation

Table 8 summarizes the radioactive decay properties of lutetium-177.

Table 8. Physical Decay Chart: Lutetium-177 Physical Half-life = 6.647 days

Hours	Fraction Remaining	Hours	Fraction Remaining
0	1.000	48 (2 days)	0.812
1	0.996	72 (3 days)	0.731
2	0.991	168 (7 days)	0.482
5	0.979	336 (14 days)	0.232
10	0.958	720 (30 days)	0.044
24 (1 day)	0.901	1080 (45 Days)	0.009

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.

12.2 Pharmacodynamics

Lutetium Lu 177 dotatate exposure-response relationships and the time course of pharmacodynamics response are unknown.

Cardiac Electrophysiology

The ability of Lutetium Lu 177 dotatate to prolong the QTc interval at the recommended dose was assessed in an open-label study in 20 patients with somatostatin receptor-positive midgut carcinoid tumors. No large changes in the mean QTc interval (i.e., > 20 ms) were detected.

12.3 Pharmacokinetics

The pharmacokinetics (PK) of lutetium Lu 177 dotatate have been characterized in patients with progressive, somatostatin receptor-positive neuroendocrine tumors.

The mean blood exposure (area under the curve) of lutetium Lu 177 dotatate at the recommended dose is 41 ng.h/mL [coefficient of variation (CV) 36%]. The mean maximum blood concentration ($C_{\max}$) for lutetium Lu 177 dotatate is 10 ng/mL (CV 50%), which generally occurred at the end of the Lutetium Lu 177 dotatate infusion.

Distribution

The mean volume of distribution (V_z) for lutetium Lu 177 dotatate is 460 L (CV 54%).

The non-radioactive lutetium Lu 175 dotatate is 43% bound to human plasma proteins.

Within 4 hours after administration, lutetium Lu 177 dotatate distributes in kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid. The co-administration of amino acids reduced the median radiation dose to the kidneys by 47% (34% to 59%) and increased the mean beta-phase blood clearance of lutetium Lu 177 dotatate by 36%.

Elimination

The mean clearance (CL) is 4.5 L/h (CV 31%) and the mean terminal half-life is 71 (± 28) hours for lutetium 177 dotatate.

Metabolism

Lutetium Lu 177 dotatate does not undergo hepatic metabolism.

Excretion

Lutetium Lu 177 dotatate is primarily eliminated renally with cumulative excretion of 44% within 5 hours, 58% within 24 hours, and 65% within 48 hours following BRAVNETSA administration. Prolonged elimination of lutetium Lu 177 dotatate in the urine is expected; however, based on the half-life of lutetium-177 and terminal half-life of lutetium Lu 177 dotatate, greater than 99% of the administered radioactivity will be eliminated within 14 days after administration of BRAVNETSA [see [Warnings and Precautions](#) (5.1)].

Drug Interaction Studies

In Vitro Studies

CYP450 enzymes: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor or inducer of cytochrome P450 (CYP) 1A2, 2B6, 2C9, 2C19 or 2D6 in vitro.

Transporters: The non-radioactive lutetium Lu 175 dotatate is not an inhibitor of P-glycoprotein, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3 in vitro.

Pediatric use information is approved for Advanced Accelerator Applications USA, Inc.'s Lutathera® (lutetium Lu 177 dotatate) injection. However, due to Advanced Accelerator Applications USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity and mutagenicity studies have not been conducted with lutetium Lu 177 dotatate; however, radiation is a carcinogen and mutagen.

No animal studies were conducted to determine the effects of lutetium Lu 177 dotatate on fertility.

13.2 Animal Toxicology and/or Pharmacology

The primary target organ in animal studies using the non-radioactive lutetium Lu 175 dotatate was the pancreas, a high SSTR2 expressing organ. Pancreatic acinar apoptosis occurred at lutetium Lu 175 dotatate doses ≥ 5 mg/kg in repeat dose toxicology studies in rats. Pancreatic acinar cell atrophy also occurred in repeat dose toxicology studies in dogs at doses ≥ 500 mcg/kg. These findings were consistent with high uptake of the radiolabeled peptide in the pancreas in animal biodistribution studies.

14 CLINICAL STUDIES

14.1 Progressive, Well-Differentiated Advanced or Metastatic Somatostatin Receptor-Positive Midgut Carcinoid Tumors

The efficacy of lutetium Lu 177 dotatate in patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumors was established in NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial. Key eligibility criteria included Ki67 index $\leq 20\%$, Karnofsky performance status ≥ 60 , confirmed presence of somatostatin receptors on all lesions (OctreoScan uptake $\geq$ normal liver), creatinine clearance ≥ 50 mL/min, no prior treatment with peptide receptor radionuclide therapy (PRRT), and no prior external beam radiation therapy to more than 25% of the bone marrow.

At the time of the primary analysis, 229 patients were randomized (1:1) to receive either lutetium Lu 177 dotatate 7.4 GBq (200 mCi) every 8 weeks (± 1 week) for up to 4 administrations (maximum cumulative dose of 29.6 GBq) or high-dose long-acting octreotide (defined as 60 mg by intramuscular injection every 4 weeks). Patients in the lutetium Lu 177 dotatate arm also received long-acting octreotide 30 mg as an intramuscular injection 4 to 24 hours after each lutetium Lu 177 dotatate dose and every 4 weeks after completion of lutetium Lu 177 dotatate treatment until disease progression or until week 76 of the study. Patients in both arms could receive short-acting octreotide for symptom management; however, short-acting octreotide was withheld at least 24 hours before each lutetium Lu 177 dotatate dose. Randomization was stratified by OctreoScan tumor uptake score (Grade 2, 3, or 4) and the length of time that patients had been on the most recent constant dose of octreotide prior to randomization (≤ 6 or > 6 months). The major efficacy outcome measure was progression-free survival (PFS) as determined by a blinded independent review committee (IRC) per RECIST v1.1. Additional efficacy outcome measures were overall response rate (ORR) by IRC, duration of response (DoR) by IRC, and overall survival (OS).

Demographic and baseline disease characteristics were balanced between the treatment arms. Of the 229 patients, 82% were White, 4% were Black, 3% were Hispanic or Latino, 0.4% were Asian, 0.4% were Other, and 9% were not reported. The median age was 64 years (28 to 87 years); 51% were male, 74% had an ileal primary, and 96% had metastatic disease in the liver. The median Karnofsky performance score was 90 (60 to 100), 74% received a constant dose of octreotide for > 6 months and 12% received prior treatment with everolimus. Sixty-nine percent of patients had Ki67 expression in $\leq 2\%$ of tumor cells, 77% had CgA > 2 times the upper limit of normal (ULN), 65% had 5-HIAA > 2 times ULN, and 65% had alkaline phosphatase $\leq$ ULN.

At the time of the final OS analysis, which occurred 66 months after the primary PFS analysis, 117 patients were randomized to the lutetium Lu 177 dotatate arm and 114 patients were randomized to the octreotide arm. In the final OS analysis, there was no statistically significant difference in OS between the two treatment arms. Efficacy results for NETTER-1 are presented in [Table 9](#) and [Figure 1](#).

Table 9. Efficacy Results in NETTER-1

	Lutetium Lu 177 dotatate with long-acting Octreotide (30 mg) N = 116	Long-acting Octreotide (60 mg) N = 113
PFS by IRC		
Events (%)	27 (23%)	78 (69%)
Progressive disease, n (%)	15 (13%)	61 (54%)
Death, n (%)	12 (10%)	17 (15%)
Median in months (95% CI)	NR (18.4, NE)	8.5 (6.0, 9.1)

Hazard ratio ^a (95% CI)	0.21 (0.13, 0.32)	
p-value ^b	< 0.0001	
ORR by IRC		
ORR, % (95% CI)	13% (7%, 19%)	4% (0.1%, 7%)
Complete response rate, n (%)	1 (1%)	0
Partial response rate, n (%)	14 (12%)	4 (4%)
p-value ^c	0.0148	
Duration of response, median in months (95% CI)	NR (2.8, NE)	1.9 (1.9, NE)


Abbreviations: CI, confidence interval; IRC, independent radiology committee; NE, not evaluable; NR, not reached; ORR, overall response rate; PFS, progression-free survival.

^aHazard ratio based on the unstratified Cox model.

^bUnstratified log rank test.

^cFisher's exact test.

Figure 1. Kaplan-Meier Curves for Progression-Free Survival in NETTER-1



14.2 Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors

The efficacy of lutetium Lu 177 dotatate in patients with foregut, midgut, and hindgut gastroenteropancreatic neuroendocrine tumors (GEP-NETs) was assessed in 360 patients in the ERASMUS study. In ERASMUS, lutetium Lu 177 dotatate was initially provided as expanded access under a general peptide receptor radionuclide therapy protocol at a single

site in the Netherlands. A subsequent lutetium Lu 177 dotatate -specific protocol written eight years after study initiation did not describe a specific sample size or hypothesis testing plan but allowed for retrospective data collection. A total of 1214 patients received lutetium Lu 177 dotatate in ERASMUS, of whom 578 patients had baseline tumor assessments. Of the 578 patients, 360 (62%) had GEP-NETs and long-term follow up. Of these 360 patients, 145 (40%) had their tumors prospectively evaluated according to RECIST criteria. Lutetium Lu 177 dotatate 7.4 GBq (200 mCi) was administered every 6 to 13 weeks for up to 4 doses concurrently with the recommended amino acid solution. The major efficacy outcome was investigator-assessed ORR. The median age in the efficacy subset was 60 years (30 to 85 years), 51% were male, 71% had a baseline Karnofsky performance status ≥ 90 , 51% had progressed within 12 months of treatment, and 7% had received prior chemotherapy. Fifty-two percent (52%) of patients received a concomitant somatostatin analog. The median dose of lutetium Lu 177 dotatate was 29.6 GBq (800 mCi). The investigator-assessed ORR was 17% (95% CI: 13, 21) based on an analysis that required responders to have had prospective response assessments according to RECIST criteria. Three complete responses were observed ($< 1\%$). Median DoR in the 60 responding patients was 35 months (95% CI: 17, 38).

16 HOW SUPPLIED/STORAGE AND HANDLING

BRAVNETSA injection containing 370 MBq/mL (10 mCi/mL) of lutetium Lu 177 dotatate is a sterile, preservative-free and clear, colorless to slightly yellow solution for intravenous use supplied in a clear, colorless Type I glass 25 mL single-dose vial containing 7.4 GBq (200 mCi) $\pm 10\%$ of lutetium Lu 177 dotatate at the time of injection (NDC# 11994-023-01). The solution volume in the vial ranges between 20.5 mL to 25 mL to provide a total of 7.4 GBq (200 mCi) of radioactivity.

Lutetium-177 is prepared using ytterbium-176 (“non-carrier added”).

The product vial is enclosed within a lead shielded container (NDC# 11994-023-01) placed in a plastic sealed container. The product is shipped in a Type A package (NDC# 11994-023-70).

Store at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). Do not freeze BRAVNETSA injection. Store in the original package to protect from ionizing radiation (lead shielding).

The shelf life is 60 hours from the date and time of calibration. Discard appropriately at 60 hours.

17 PATIENT COUNSELING INFORMATION

Risk From Radiation Exposure

Advise patients and/or caregivers to minimize radiation exposure to household contacts during and after treatment with BRAVNETSA consistent with institutional good radiation safety practices and patient management procedures [see *Dosage and Administration* (2.1), *Warnings and Precautions* (5.1)].

Myelosuppression

Advise patients and/or caregivers to contact their healthcare provider for any signs or symptoms of myelosuppression or infection [see *Warnings and Precautions* (5.2)].

Secondary Myelodysplastic Syndrome and Leukemia

Advise patients and/or caregivers of the potential for secondary cancers, including myelodysplastic syndrome and acute leukemia [see *Warnings and Precautions* (5.3)].

Renal Toxicity

Advise patients and/or caregivers to hydrate and to urinate frequently before, on the day of, and the day after administration of BRAVNETSA [see *Warnings and Precautions* (5.4)]. Advise patients to contact their healthcare provider for any signs or symptoms of renal toxicity [see *Warnings and Precautions* (5.4)].

Hepatotoxicity

Advise patients and/or caregivers of the need for periodic laboratory tests to monitor for hepatotoxicity [see *Warnings and Precautions* (5.5)]. Advise patients to contact their healthcare provider for any signs or symptoms of hepatotoxicity [see *Warnings and Precautions* (5.5)].

Hypersensitivity

Advise patients and/or caregivers that BRAVNETSA may cause hypersensitivity reactions, including angioedema, and to seek immediate medical attention for signs or symptoms of hypersensitivity [see *Warnings and Precautions* (5.6)].

Neuroendocrine Hormonal Crises

Advise patients and/or caregivers to contact their healthcare provider for signs or symptoms that may occur following tumor-related hormonal release [see *Warnings and Precautions* (5.7)].

Embryo-Fetal Toxicity

Advise pregnant women and males and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions* (5.8), *Use in Specific Populations* (8.1, 8.3)].

Advise females of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 7 months after the last dose [see *Use in Specific Populations* (8.1, 8.3)].

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with BRAVNETSA and for 4 months after the last dose [see *Use in Specific Populations* (8.1, 8.3)].

Lactation

Advise females not to breastfeed during treatment with BRAVNETSA and for 2.5 months after the last dose [see *Use in Specific Populations* (8.2)].

Infertility

Advise female and male patients that BRAVNETSA may impair fertility [see *Warnings and Precautions* (5.9), *Use in Specific Populations* (8.3)].

Manufactured by:
Point Biopharma USA Inc.
4850 W 78th St
Indianapolis, IN 46268

Distributed by:
Lantheus Medical Imaging
331 Treble Cove Road
N. Billerica, MA 01862
For ordering, call toll free: 800-299-3431
All Other Business: 800-362-2668
(For Massachusetts and International, call 978-667-9531)

BRAVNETSA is a trademark of Lantheus Medical Imaging, Inc. and/or its affiliates. All other trademarks are the property of their respective owners.

516150-0926